Anticonvulsant activities of nutmeg oil of Myristica fragrans

Phytotherapy Research

Volumn 23, Issue 2, 2009, Pages 153-158

  Wahab, Abdul ^a,b   Haq, Rizwan Ul ^a,b   Ahmed, Aftab ^a   Khan, Rafeeq Alam ^a   Raza, Mohsin ^c  

^a UNIVERSITY OF KARACHI   (Pakistan)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Acute toxicity; Anticonvulsant; Epilepsy; Myristica fragrans; Nutmeg oil; Seizure

Indexed keywords

NUTMEG OIL; ANTICONVULSIVE AGENT; ESSENTIAL OIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CLONIC SEIZURE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; LD 50; MALE; MOUSE; NEUROTOXICITY; NONHUMAN; PLANT SEED; SEIZURE; ANIMAL; CHEMICALLY INDUCED DISORDER; CHEMISTRY; DISEASE MODEL; DOSE RESPONSE; ELECTRIC SHOCK; MOTOR ACTIVITY; NUTMEG; TOXICITY TESTING;

ANIMALIA; MYRISTICA FRAGRANS; STRYCHNOS TOXIFERA;

ANIMALS; ANTICONVULSANTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROSHOCK; LETHAL DOSE 50; MALE; MICE; MOTOR ACTIVITY; MYRISTICA FRAGRANS; OILS, VOLATILE; SEIZURES; TOXICITY TESTS;

EID: 59449088247     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.2548     Document Type: Article

References (39)

1. Abelson PH. 1990. Medicine from plants. Science 247: 513.
2. Anonymous. 2002. Compendium of Medicinal Plants Used in Malaysia. Vol. 2. Herbal Medicine Research Center, Institute for Medical Research: Kuala Lumpur, Malaysia.
3. Arroyo S, Brodie MJ, Avanzini G et al. 2002. Is refractory epilepsy preventable? Epilepsia 43: 437-444.
4. Atta-ur-Rahman, Choudhary MI, Farooq A et al. 2000. Antifungal activities and essential oil constituents of some spices from Pakistan. J Chem Soc Pak 22: 60-65.
5. Bell GS, Sander JW. 2001. The epidemiology of epilepsy: the size of the problem. Seizure 10: 306-314.
6. Braun U, Kalbhen DA. 1973. Evidence for the biogenic formation of amphetamine derivatives from components of nutmeg. Pharmacology 9: 312-316.
7. Brum LF, Elisabetsky E, Souza D. 2001. Effects of linalool on [(3)H]MK801 and [(3)H] muscimol binding in mouse cortical membranes. Phytother Res 15: 422-425.
8. Consroe P, Martin A, Singh V. 1981. Antiepileptic potential of cannabidiol analogs. J Clin Pharmacol21(Suppl 8-9): S428-S436.
9. Coughenour LL, McLean JR, Parker RB. 1977. A new device for the rapid measurement of impaired motor function in mice. Pharmacol Biochem Behav 6: 351-353.
10. Curtis DR, Duggan AW, Felix D, Johnston GA. 1970. Bicuculline and central GABA receptors. Nature 228(5272): 676-677.
11. Dallmeier K, Carlini EA. 1981. Anesthetic, hypothermic, myo-relaxant and anticonvulsant effects of synthetic eugenol derivatives and natural analogues. Pharmacology 22: 113-127.
12. Elisabetsky E, Silva Brum LF, Souza DO. 1999. Anticonvulsant properties of linalool in glutamate-related seizure models. Phytomedicine 6: 107-113.
13. Elisabetsky E, Souza GPC, Santos MAC, Siqueira IR, Amador TA, Nunes DS. 1995. Sedative properties of linalool. Fitoterapia 66: 407-414.
14. Farnsworth NR. 1968. Hallucinogenic plants. Various chemical substances are known to be the active hallucinogenic principles in many plants. Science 162(858): 1086-1092.
15. Gelisse P, Genton P, Kuate C, Pesenti A, Baldy-Moulinier M, Crespel A. 2004. Worsening of seizures by oxcarbazepine in juvenile idiopathic generalized epilepsies. Epilepsia 45:1282-1286.
16. Genton P. 2000. When antiepileptic drugs aggravate epilepsy. Brain Dev 22: 75-80.
17. Heinrich M. 2000. Ethnobotany and its role in drug development. Phytother Res 14: 479-488.
18. Joshi SG. 2000. Medicinal Plants. Oxford and IBH Publishing Co. Pvt. Ltd: New Delhi, Calcutta.
19. Kalbhen DA. 1971. Nutmeg as a narcotic. A contribution to the chemistry and pharmacology of nutmeg (Myristica fragrans). Angew Chem (International Edition in English) 10: 370-374.
20. Lorke D. 1983. A new approach to practical acute toxicity testing. Arch Toxicol 54: 275-287.
21. Loscher W, Schmidt D. 1988. Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations. Epilepsy Res 2: 145-181.
22. Loscher W, Honack D, Fassbender CP, Nolting B. 1991. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. III. Pentylenetetrazole seizure models. Epilepsy Res 8: 171-189.
23. Loscher W, Nolting B, Fassbender CP. 1990. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. I. The influence of administration vehicles. Epilepsy Res 7: 173-181.
24. Loscher W, Schmidt D. 1994. Strategies in antiepileptic drug development: Is rational drug design superior to random screening and structural variation? Epilepsy Res 17: 95-134.
25. Mhaskar KS, Blatter E, Caius JF (eds). 2000. Kirtikar and Basu's Illustrated Indian Medicinal Plants: Their Usage in Ayurveda and Unani Medicines, 3rd revised and enlarged edn, Vol. 9. Sri Satguru Publications: Delhi, India; 2954-2955.
26. Moreira MR, Cruz GM, Lopes MS, Albuquerque AA, Leal-Cardoso JH. 2001. Effects of terpineol on the compound action potential of the rat sciatic nerve. Braz J Med Biol Res 34: 1337-1340.
27. Pranzatelli MR, Nadi NS. 1995. Mechanism of action of antiepileptic and antimyoclonic drugs. In Negative Motor Phenomena. Advances in Neurology, Fahn S, Hallett M, Luders HO, Marsden CD (eds). Vol. 67. Lippincott-Raven: Philadelphia; 329-360.
28. Rajendra S, Lynch JW, Schofield PR. 1997. The glycine receptor. Pharmacol Ther 73: 121-146.
29. Raza M, Choudhary MI, Atta-ur-Rahman. 2000. Medicinal plants with anticonvulsant activities. In Studies in Natural Product Chemistry, Atta-ur-Rahman (ed.). Vol. 22. Elsevier Science: Netherlands; 507-553.
30. Raza M, Shaheen F, Choudhary MI et al. 2001a. Anticonvulsant activities of ethanolic extract and aqueous fraction isolated from Delphinium denudatum. J Ethnopharmacol 78: 73-78.
31. Raza M, Shaheen F, Choudhary MI et al. 2001b. Anticonvulsant activities of the FS-1 subfraction isolated from roots of Delphinium denudatum. Phytother Res 15: 426-430.
32. Rumke CL. 1967. Increased susceptibility of mice to seizures after some anticonvulsant drugs. Eur J Pharmacol 1: 369-377.
33. Schmidt D. 2002. The clinical impact of new antiepileptic drugs after a decade of use in epilepsy. Epilepsy Res 50: 21-32.
34. Shulgin AT. 1966. Possible implication of myristicin as a psychotropic substance. Nature 210: 380-384.
35. Swinyard EA, Kupferberg HJ. 1985. Antiepileptic drugs: detection, quantification and evaluation. Fed Proc 44: 2629-2633.
36. Swinyard EA, Sofia RD, Kupferberg HJ. 1986. Comparative anti- convulsant activity and neurotoxicity of felbamate and four prototypes antiepileptic drugs in mice and rats. Epilepsia 27: 27-34.
37. van Noordwijk AJ, van Noordwijk J. 1988. An accurate method for estimating an approximate lethal dose with few animals, tested with a Monte Carlo procedure. Arch Toxicol 61: 333-343.
38. White HS. 1999. Comparative anticonvulsant and mechanistic profile of the established and newer antiepileptic drugs. Epilepsia 40(Suppl 5): S2-S10.
39. White HS, Wolf HH, Woodhead JH, Kupferberg HJ. 1998. The National Institute of Health Anticonvulsant Drug Development Program: screening for efficacy. In Antiepileptic Drug Development: Advances in Neurology, French JA, Leppik IE, Dichter MA (eds). Vol. 76. Lippincott-Raven Publishers: Philadelphia; 29-39.